Albireo Pharma Inc. (ALBO)’s Financial Results Comparing With Flex Pharma Inc. (NASDAQ:FLKS)

Albireo Pharma Inc. (NASDAQ:ALBO) and Flex Pharma Inc. (NASDAQ:FLKS) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Albireo Pharma Inc. 12.17M 25.04 35.30M -3.01 0.00
Flex Pharma Inc. N/A 6.01 27.94M -1.56 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Albireo Pharma Inc. and Flex Pharma Inc.


Table 2 has Albireo Pharma Inc. and Flex Pharma Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Albireo Pharma Inc. -290.06% 0% 0%
Flex Pharma Inc. 0.00% -148.1% -121.3%

Volatility & Risk

Albireo Pharma Inc.’s current beta is 1.78 and it happens to be 78.00% more volatile than Standard and Poor’s 500. In other hand, Flex Pharma Inc. has beta of 1.76 which is 76.00% more volatile than Standard and Poor’s 500.


The Current Ratio and a Quick Ratio of Albireo Pharma Inc. are 19.4 and 19.4. Competitively, Flex Pharma Inc. has 4.7 and 4.7 for Current and Quick Ratio. Albireo Pharma Inc.’s better ability to pay short and long-term obligations than Flex Pharma Inc.

Institutional & Insider Ownership

Roughly 83% of Albireo Pharma Inc. shares are owned by institutional investors while 30.6% of Flex Pharma Inc. are owned by institutional investors. Albireo Pharma Inc.’s share owned by insiders are 0.5%. Insiders Competitively, owned 21.8% of Flex Pharma Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Albireo Pharma Inc. -4.16% -8.75% -23.37% -22.26% 1.77% -0.98%
Flex Pharma Inc. -2.35% -24.79% -9.72% -89.98% -88.71% -87.97%

For the past year Albireo Pharma Inc. has stronger performance than Flex Pharma Inc.


Albireo Pharma Inc. beats Flex Pharma Inc. on 6 of the 9 factors.

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.